<DOC>
	<DOCNO>NCT03004599</DOCNO>
	<brief_summary>Safety Efficacy SYM-SV/DS-002 Patients Severe Aortic Stenosis</brief_summary>
	<brief_title>Safety Efficacy SYM-SV/DS-002 Patients With Severe Aortic Stenosis</brief_title>
	<detailed_description>To evaluate safety efficacy Transfemoral Transcatheter Aortic Valve Implantation use SYM-SV-002 Aortic Bioprosthesis SYM-DS-002 Transfemoral Delivery System patient present symptomatic severe aortic stenosis difficulty safely undergo conventional surgical aortic valve replacement ( AVR )</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . At least one cardiologist one cardiac surgeon agree difficult patient receive surgical procedure due medical factor subject various comorbidities he/she likely die suffer severe disease significant improvement surgical procedure . 2 . Subject senile degenerative aortic valve stenosis : mean gradient &gt; 40 mmHg , maximum jet velocity great 4.0 m/sec either rest dobutamine stress echocardiogram , simultaneous pressure recording cardiac catheterization AND initial aortic valve area ≤ 0.8 cm2 ( aortic valve area index ≤ 0.5 cm2/m2 ) rest echocardiogram simultaneous pressure recording cardiac catheterization 3 . Subject symptomatic his/her aortic valve stenosis ( AS ) , demonstrate New York Heart Association ( NYHA ) Functional Class II great . 4 . The subject informed nature trial , agree provision provide write informed consent approve IRB respective clinical site . 5 . The subject subject 's legal representative agree visit site he/she receive index procedure require postprocedure followup . 1 . Evidence acute myocardial infarction ≤ 30 day ( The procedure day count day 0 . ) implant procedure 2 . Any percutaneous coronary peripheral interventional procedure , include placement bare metal stent perform within 30 day prior implant procedure , drug elute stent place within 6 month ( One month count 30 day . ) prior implant procedure 3 . Untreated clinically significant coronary artery disease ( CAD ) require revascularization 4 . Blood dyscrasia define : leukopenia ( WBC &lt; 1,000/mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy 5 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support 6 . Need emergency surgery reason 7 . Severe ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % measure rest echocardiogram 8 . Cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within 6 month prior implant procedure ( except mild TIA relate aortic stenosis ) 9 . End stage renal disease require chronic dialysis serum creatinine &gt; 3.0 mg/dL 10 . Active Gastrointestinal ( GI ) bleed within 3 month prior implant procedure 11 . A known hypersensitivity contraindication follow adequately premedicated : Aspirin Heparin ( HIT/HITTS ) Nitinol ( titanium nickel ) P2Y12 inhibitor ( Ticlopidine etc . ) Contrast medium 12 . Ongoing sepsis , include active endocarditis 13 . Subject refuse blood transfusion 14 . Life expectancy &lt; 12 month due associate noncardiac comorbid condition 15 . Other medical , social , psychological condition opinion principal investigator subinvestigator precludes subject appropriate consent 16 . Severe dementia ( unable provide inform consent treatment/procedure , unable live independent life outside chronic care facility , expect fundamentally unable undergo rehabilitation procedure , unable come site followup visit ) 17 . Currently participate trial investigational drug investigational device 18 . Native aortic annulus size &lt; 21 mm &gt; 27 mm per baseline diagnostic imaging 19 . Preexisting prosthetic heart valve / prosthetic ring position 20 . Mixed aortic valve disease ( aortic stenosis predominant aortic regurgitation ( 34+ ) ) 21 . Moderate severe ( 34+ ) severe ( 4+ ) mitral regurgitation severe ( 4+ ) tricuspid regurgitation 22 . Moderate severe mitral stenosis 23 . Hypertrophic obstructive cardiomyopathy 24 . New untreated echocardiographic evidence intracardiac mass , thrombus vegetation 25 . Congenital bicuspid unicuspid valve verify echocardiograph 26 . Extreme eccentric calcification native aortic valve 27 . Transesophageal echocardiogram ( TEE ) contraindicate . 28 . Scheduled surgical percutaneous procedure perform prior 1month visit postimplant procedure 29 . Hepatic failure ( Child C ) 30 . Aortic peripheral condition NOT appropriate transfemoral implant due size , disease degree calcification tortuosity aorta iliofemoral artery 31 . Thoracic abdominal aortic aneurysm 32 . Woman pregnant , breastfeed willing become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Critical Aortic Stenosis</keyword>
	<keyword>Severe Aortic Stenosis</keyword>
	<keyword>High Risk</keyword>
	<keyword>Aortic Valve Replacement</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Heart Valve Therapy</keyword>
	<keyword>Transcatheter</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>TAVI</keyword>
	<keyword>TAVR</keyword>
	<keyword>ACURATE neo™ Aortic Bioprosthesis</keyword>
	<keyword>ACURATE TF™ Transfemoral Delivery System</keyword>
</DOC>